Central Nervous System News and Research

RSS

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009

Nanoscaffolds could play a central role in tissue and organ reconstruction

Researchers from the University of Hong Kong and the Massachusetts Institute of Technology have published a study in the current issue of Cell Transplantation (18:9), now freely available on line at http://www.ingentaconnect.com/content/cog/ct, that explores ways to successfully keep stem cells "forever young" during implantation by slowing their growth, differentiation and proliferation.

28 Dec 2009

Publication validates company's structure-based approach for addressing undruggable targets

28 Dec 2009

Learning disabilities: Understanding the problem and managing the challenges

"Trying to address learning disabilities with innovative teaching methods and creative school financing is not the answer," said Etta Brown, a licensed educational psychologist, veteran social worker and author of "Learning Disabilities, Understanding the Problem and Managing the Challenges" from Langdon Street Press (www.understandingld.com).

24 Dec 2009

Novel discovery offers hope for patients with common brain tumor

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults.

23 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

UAB professors honored for scientific contributions and outstanding mentorship

Three University of Alabama at Birmingham (UAB) professors have been elected fellows of the American Association for the Advancement of Science (AAAS).

18 Dec 2009

First IOF Regional Osteoporosis Meeting in the Asia Pacific region

Mark December 10-13, 2010 on your calendar and don't miss this important scientific event, organised by the International Osteoporosis Foundation (IOF).

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

AANS and CNS oppose Senate healthcare reform

The American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) have joined thousands of other physicians from 12 medical specialty organizations to deliver an urgent message to the public and to Congress: we need reform, but this isn’t the right reform; urge your Senator to vote “NO” on the Patient Protection and Affordable Care Act (H.R. 3590) as introduced by Senate Majority Leader Harry Reid.

18 Dec 2009

Adimab announces initiation of research collaborations with two other companies

Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of research collaborations with Pfizer and an undisclosed second company. Adimab also announced the receipt of milestone payments from two recently announced discovery collaborations with Merck and Roche.

17 Dec 2009

Investigational study of TRT to alleviate debilitating effects of tinnitus commenced

A University of Alabama researcher is embarking on a $5.6 million phase-three, randomized, controlled clinical trial to evaluate the effectiveness of an innovative treatment that uses a noise-generating device, along with counseling, to alleviate the debilitating effects of tinnitus - that ringing in the ears that drives some people to distraction.

17 Dec 2009

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

GOLFING icon Seve Ballesteros yesterday (Monday 14th December) joined forces with Cancer Research UK in a bid to beat brain cancer. Seve said he was 'lucky to be alive and owed it all to important research many people have carried out in the past'.

17 Dec 2009

EMD Serono, Brigham and Women's Hospital collaborate in MS research

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Higher leptin levels associated with lower incidence of AD and dementia

Persons with higher levels of leptin, a protein hormone produced by fat cells and involved in the regulation of appetite, may have an associated reduced incidence of Alzheimer disease and dementia, according to a study in the December 16 issue of JAMA.

16 Dec 2009

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.

15 Dec 2009

Psychopharmacology expert calls for more mental health staffing at army bases

The recent shootings at the Ft. Hood, Texas army base, allegedly by an army psychiatrist, have placed much-needed focus on mental health care in the army. In an article published in the December issue of the journal CNS Spectrum, renowned psychopharmacology expert Stephen M. Stahl, MD, PhD, calls for increased mental health staffing at Fort Hood and other army bases.

14 Dec 2009

Central Nervous System News and Research

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Nanoscaffolds could play a central role in tissue and organ reconstruction

Publication validates company's structure-based approach for addressing undruggable targets

Learning disabilities: Understanding the problem and managing the challenges

Novel discovery offers hope for patients with common brain tumor

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

UAB professors honored for scientific contributions and outstanding mentorship

First IOF Regional Osteoporosis Meeting in the Asia Pacific region

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

AANS and CNS oppose Senate healthcare reform

Adimab announces initiation of research collaborations with two other companies

Investigational study of TRT to alleviate debilitating effects of tinnitus commenced

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

EMD Serono, Brigham and Women's Hospital collaborate in MS research

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Higher leptin levels associated with lower incidence of AD and dementia

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Psychopharmacology expert calls for more mental health staffing at army bases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News